Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events

Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events

August 31, 2026Posted inBiotechnology

Novartis and Bristol Myers Squibb have halted several CAR-T trials in autoimmune diseases due to immune-related adverse events, Fierce has learned.

Post navigation

Previous Post
key-immune-cells-identified-that-could-strengthen-flu-vaccines Key Immune Cells Identified That Could Strengthen Flu Vaccines
Next Post
‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer ‘one-two-punch’-targets-resistance-mechanism-in-aggressive-triple-negative-breast-cancer

Recent Posts

  • Spatial Transcriptomics Tools May Link Tumor Organization to Treatment Response
  • Single-Use Comes of Age—What Comes Next?
  • ‘One-Two Punch’ Targets Resistance Mechanism in Aggressive Triple-Negative Breast Cancer
  • Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events
  • Key Immune Cells Identified That Could Strengthen Flu Vaccines

Archives

  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top